Microsoft’s Stock Rises 9% As Financial Results Top Estimates
Microsoft’s (MSFT) stock is up nearly 10% after the technology giant reported financial results for this year’s first quarter that topped Wall Street estimates.The Seattle-based company announced earnings per share (EPS) of $3.46 U.S., which beat forecasts that called for $3.22 U.S. Revenue in the period totaled $70.07 billion U.S., which was ahead of the $68.42 billion U.S. estimated among analysts. Overall sales were up 13% from a year earlier.The company said that revenue from its Azure cloud computing unit grew 33% during Q1, with 16 percentage points of that growth coming from artificial intelligence (AI). Analysts had forecast 30% Azure revenue growth.The company’s Intelligent Cloud unit that includes Azure produced $26.75 billion U.S. in sales, up 21% year-over-year.Microsoft’s Productivity and Business Processes segment, which contains Office software subscriptions and LinkedIn, contributed $29.94 billion U.S. in revenue, up 10% from a year ago. Revenue from the More Personal Computing unit that contains Windows, search advertising, devices, and the Xbox video game console, came in at $13.37 billion U.S., an increase of 6%. Microsoft remains focused on advancing it’s A.I. technologies, committing to spend $80 billion U.S. in capital on A.I. data centers in the current fiscal year. Prior to today (May 1), the stock of Microsoft had declined 6% this year to trade at $395.26 U.S. per share.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


